Collins Stewart Downgrades Dendreon (DNDN) to Neutral; Reimbursement Headwinds and Demand Up in the Air
Tweet Send to a FriendGet Alerts DNDN Hot Sheet
Price: $3.89 -0.51%
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade DNDN Now!
Collins Stewart downgraded Dendreon (NASDAQ: DNDN) rom Buy to Neutral, price target slashes from $55 to $19.
Collins analyst says, "Given July Provenge sales of ~$19M (vs. ~$15M in April) and ~0.8 patients/month/account (vs. 1-2 expected) in 2Q, we wonder if the shortfall is solely attributable to DNDN's aforementioned issues or reflective of a lack of demand (physicians want to see tangible PSA/PFS benefit) and/or competition (Zytiga) and may call the CRPC market size into question. We are stepping to the sidelines until we gain clarity on the root causes behind the slower uptake and look to 3Q for insight into the role of the NCD and Q-code in alleviating reimbursement concerns. We are lowering our 3Q11+ Provenge U.S. revenue estimates and now model for peak sales of ~$1B (vs. $2B prior) in FY16."
For more ratings news on Dendreon click here and for the rating history of Dendreon click here.
Shares of Dendreon closed at $35.84 yesterday, with a 52 week range of $31.31-$43.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Collins analyst says, "Given July Provenge sales of ~$19M (vs. ~$15M in April) and ~0.8 patients/month/account (vs. 1-2 expected) in 2Q, we wonder if the shortfall is solely attributable to DNDN's aforementioned issues or reflective of a lack of demand (physicians want to see tangible PSA/PFS benefit) and/or competition (Zytiga) and may call the CRPC market size into question. We are stepping to the sidelines until we gain clarity on the root causes behind the slower uptake and look to 3Q for insight into the role of the NCD and Q-code in alleviating reimbursement concerns. We are lowering our 3Q11+ Provenge U.S. revenue estimates and now model for peak sales of ~$1B (vs. $2B prior) in FY16."
For more ratings news on Dendreon click here and for the rating history of Dendreon click here.
Shares of Dendreon closed at $35.84 yesterday, with a 52 week range of $31.31-$43.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'
- Macquarie Downgrades Melco Crown Enter. (MPEL) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Collins Stewart
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
